Pradaxa · DIN 02358808 · 150 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Pradaxa · DIN 02358808
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-04-24
Health Canada: Marketed since 2013-03-28 · brand PRADAXA · ATC B01AE07 DABIGATRAN ETEXILATE · form Capsule · route Oral · ingredients DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE MESILATE) 150 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Ministry pays: $1.2540 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02358808)
Source record
DIN 02358808: Pradaxa
Raw flags: sec3=Y
Item: 201200085; group id 252; item number 0447; lccId None; manufacturer id BOE
Source form: Cap; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $1.8060; ministry $1.2540
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02358808
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84384
Interchangeable products
Apo-Dabigatran · DIN 02468913 · $1.2540
Shortage status: resolved shortage (ended February 1, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358808
Shortage record checked October 6, 2026